trial · primary record
Romidepsin
Bladder Cancer
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 12 |
| Primary completion | 2028-04 |
| Primary endpoint | Romidepsin Maximum Tolerated Dose (MTD) |
| Registry ID | NCT06963346 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:05.114Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06963346
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.